Sample size justification in phase III/IV clinical trials

Neuroepidemiology

Volumn 17, Issue 2, 1998, Pages 63-66

  Richardson, DeJuran ^a   Leurgans, Sue ^a  

^a AAASPS Data Management Center   (United States)

Author keywords

Clinical trial design; Power; Sample size

Indexed keywords

CLINICAL RESEARCH; HUMAN; REVIEW; SAMPLING; SECONDARY PREVENTION; STROKE;

CLINICAL TRIALS, PHASE III; CLINICAL TRIALS, PHASE IV; EPIDEMIOLOGIC STUDIES; HUMANS; RESEARCH DESIGN; SAMPLE SIZE;

EID: 0031892460     PISSN: 02515350     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026154     Document Type: Review

References (5)

1. Collins JF, Williford WO, Weiss DG, Bingham SF, Klett CJ: Planning patient recruitment: Fantasy and reality. Stat Med 1984;3:435-443.
2. The Steering Committee of the Physicians' Health Study. Preliminary report: Findings from the aspirin component of the ongoing physicians' Health Study. New Engl J Med 1988;318:262-264.
3. Gould AL: Planning and revising the sample size for a trial. Stat Med 1995;14:1039-1051.
4. Wittes J, Brittain E: The role of internal pilot studies in increasing the efficiency of clinical trials. Stat Med 1990;9:65-72.
5. Freedman LS: Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1982;1:121-129.